We submit here a proposal for renewal of the Pharmacogenomics of Arrhythmia Therapy (PAT) node of the PGRN. The studies we propose combine candidate, genome-wide, and targeting resequencing approaches to identify the genomic basis for arrhythmia drug response phenotypes of major public health importance. In addition, each Specific Aim includes a major focus on multi-institutional accumulation of large numbers of patients with well-defined drug response phenotypes. Studies In Specific Aim 1 further define the genomic basis underlying susceptibility to drug-induced long QT-related arrhythmias, a continuing challenge In clinical drug use and In drug development.
In Specific Aim 2, we build on previous work to prospectively assess the relationships among drug response, genotypes, and clinical endophenotypes in patients with atrial fibrillation (AF). While AF therapy often includes warfarin anticoagulation whose major complication is bleeding, pharmacogenomic studies of warfarin response to date have focused on determinants of dose.
In Specific Aim 3, we will identify a large set of cases of major warfarin-related bleeding in BioVU, our DNA repository linked to de-identified electronic medical records, and undertake a case-control study of the genomic determinants of this complication. We include here two proposals for network resources: (1) PGPop (PharmacoGenomic discovery and replication in very large patient Populations) that brings together multiple healthcare system-based nodes, including BioVU, that each Include extensive drug response phenotypes and extant or planned large DNA collections. PGPop will serve as a "real-world" platform for pharmacogenomic discovery;one initial project will be generation of a replication set for warfarin-related bleeding. (2) P-STAR (PGRN Statistical Analysis Resource), that will provide statistical support to PGRN sites and develop advanced methods in the field. These studies build on progress within our own site, across PGRN, and reach out beyond the network to develop expanded populations and new tools to enable application of pharmacogenetic knowledge to clinical care.
We build here on previous progress to understand the genomic basis of variability in drug response among patients with cardiac arrhythmias, a continuing public health problem. The methods we adopt have the potential not only to affect our understanding of arrhythmia pharmacogenomics but also to more generally refine and expand our approaches to the problem of variable drug responses.
|Bush, W S; Crosslin, D R; Owusu-Obeng, A et al. (2016) Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network. Clin Pharmacol Ther 100:160-9|
|Barrett, Tyler W; Self, Wesley H; Darbar, Dawood et al. (2016) Association of atrial fibrillation risk alleles and response to acute rate control therapy. Am J Emerg Med 34:735-40|
|Bersell, Kevin; Montgomery, Jay A; Kanagasundram, Arvindh N et al. (2016) Partial Duplication and Poly(A) Insertion in KCNQ1 Not Detected by Next-Generation Sequencing in Jervell and Lange-Nielsen Syndrome. Circ Arrhythm Electrophysiol 9:|
|Huang, Henry; Darbar, Dawood (2016) Gene-guided therapy for catheter-ablation of atrial fibrillation: are we there yet? J Interv Card Electrophysiol 45:3-5|
|Daneshjou, Roxana; Cavallari, Larisa H; Weeke, Peter E et al. (2016) Population-specific single-nucleotide polymorphism confersÂ increased risk of venous thromboembolism in African Americans. Mol Genet Genomic Med 4:513-20|
|Roden, Dan M (2016) Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet 61:79-85|
|Lin, Honghuang; Mueller-Nurasyid, Martina; Smith, Albert V et al. (2016) Gene-gene Interaction Analyses for Atrial Fibrillation. Sci Rep 6:35371|
|Darbar, Dawood (2016) The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight? J Cardiovasc Pharmacol 67:9-18|
|McCauley, Mark; Vallabhajosyula, Sharath; Darbar, Dawood (2016) Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients. Card Electrophysiol Clin 8:481-93|
|Roden, Dan M (2016) Pharmacogenetics of Potassium Channel Blockers. Card Electrophysiol Clin 8:385-93|
Showing the most recent 10 out of 214 publications